CRYSTAL PHARMATECH CO., LTD.
23Patents
23Active
23Granted
46Portfolio score
Filing activity: Nov 20, 2014 → Mar 25, 2019
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10246418B2 | Crystal form of lenvatinib methanesulfonate salt and preparation method thereof | Chemistry; Metallurgy | 5 | Active |
| US9994579B2 | Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt | Chemistry; Metallurgy | 3 | Active |
| US9751889B2 | Crystalline form I of ibrutinib | Chemistry; Metallurgy | 2 | Active |
| US9957240B2 | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof | Chemistry; Metallurgy | 1 | Active |
| US10323035B2 | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof | Chemistry; Metallurgy | 1 | Active |
| US10577334B2 | Crystalline form E of tafamidis meglumine, process for preparation and use thereof | Chemistry; Metallurgy | 1 | Active |
| US9969701B2 | Salts and co-crystals of lesinurad | Chemistry; Metallurgy | 1 | Active |
| US10544129B2 | Crystalline forms of AP26113, and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10308641B2 | Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10138239B2 | Preparation method of crystalline form a of PCI-32765 | Physics | 0 | Active |
| US10138250B2 | Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt | Chemistry; Metallurgy | 0 | Active |
| US10266523B2 | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof | Chemistry; Metallurgy | 0 | Active |
| US10351536B2 | Crystalline forms of lesinurad and its sodium salt | Chemistry; Metallurgy | 0 | Active |
| US10233144B2 | Crystalline form of AHU377, preparation method and use thereof | Chemistry; Metallurgy | 0 | Active |
| US10196395B2 | Crystalline form alpha of IPI-145 and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10273262B2 | Crystalline form A of obeticholic acid and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10508087B2 | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof | Chemistry; Metallurgy | 0 | Active |
| US10472369B2 | Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate | Chemistry; Metallurgy | 0 | Active |
| US10487064B1 | Crystalline forms of selective S1P1 receptor modulator and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10562855B2 | Crystalline form of lenvantinib mesylate and process of preparation thereof | Chemistry; Metallurgy | 0 | Active |
| US10246437B2 | Crystal form of neratinib maleate and preparation method therefor | Chemistry; Metallurgy | 0 | Active |
| US10377757B2 | Crystal form of JAK inhibitor and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US10442775B2 | Preparation method for eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.